|
 |
 |
 |
 |
 |
 |
- Home
- Join or Change Subscription
- GSI Community
- For New Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
 | |
 | |
STA-9090
A Phase I trial of STA-9090, a new inhibitor of heat shock protein 90 (Hsp90), was begun in November 2007 at Dana-Farber Cancer Institute. The lead investigator is Geoffrey Shapiro, MD PhD. This trial uses a twice-per-week dosing schedule.
In addition, in January 2008 Synta announced the initiation of a second Phase I trial with a once-per-wek dosing schedule, as described in this news story.
A press release from manufacturer Synta Pharmaceuticals included these statements: "In preclinical studies, STA-9090 has shown the ability to inhibit multiple kinases with comparable potency to, and a broader activity profile than specific kinase inhibitors such as imatinib (Gleevec(R)), erlotinib (Tarceva(R)), and sunitinib (Sutent(R)). In addition, STA-9090 has shown potency 10 to 100 times greater than the geldanamycin family of Hsp90 inhibitors, as well as activity against a wider range of kinases. In in vivo models, STA-9090 has shown strong efficacy in a wide range of cancer types, including cancers resistant to Gleevec, Tarceva, and Sutent."
These trials are not yet listed at clinicaltrials.gov.
Press release at manufacturer's website: http://ir.syntapharma.com/releasedetail.cfm?ReleaseID=274813
Manufacturer's website: http://www.syntapharma.com/
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
